Research, Collaboration and License Agreements - Additional Information (Details)	1 Months Ended			3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 31, 2020 USD ($)	Aug. 31, 2020 USD ($)	Apr. 30, 2020 Product	Sep. 30, 2025 USD ($) shares	Sep. 30, 2024 USD ($)	Sep. 30, 2025 USD ($) shares	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2024 shares	Oct. 29, 2020 USD ($)	Nov. 30, 2019 shares
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock, shares issued | shares				273,915,373		273,915,373					204,943,306
Research and development				$ 25,745,000	$ 14,946,000	$ 61,451,000	$ 50,676,000
UT Southwestern Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Preclinical activities period under sponsored research agreements			2 years
Minimum licensed product to develop obtain regulatory approval for and commercialize | Product			1
Common stock, shares issued | shares													2,179,000
Percentage of fully diluted common stock shares outstanding													20.00%
Abeona CLN1 Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional milestone payments						0
License fee payment		$ 3,000,000
Purchase of clinical materials and reimbursement incurred development costs	$ 4,000,000
Research and development									$ 3,000,000	$ 7,000,000
Abeona CLN1 Agreements | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License and inventory purchase agreement regulatory related milestones payment		26,000,000
License and inventory purchase agreement sales related milestones payment		$ 30,000,000
Abeona | Abeona Rett Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional milestone payments						0
Research and development						$ 1,000,000.0		$ 3,500,000
Payment of one-time upfront license fee										$ 3,000,000
Abeona | Maximum | Abeona Rett Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Regulatory related milestones obligation payable												$ 26,500,000
Sale-related milestones per licensed product and royalties on net sales of licensed products payable												$ 30,000,000